MentionFox
Home › Stakes › Promis Neurosciences Inc.
5%+ stakes · Schedule 13D and 13G

Promis Neurosciences Inc.: 5%+ holders

Who has reported owning 5% or more of Promis Neurosciences Inc., from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

At 5% or more10
Filings24
Latest filing2026-08-14

Promis Neurosciences Inc. has 24 Schedule 13D or 13G filings on record since 2025-07-31. 10 holders' latest filing reports 5% or more of common shares, no par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
ABG Management Ltd.17%572,677SCHEDULE 13D/A, 2026-02-052026-02-03
Jeremy M. Sclar16.9%9,511,930SCHEDULE 13G/A, 2025-10-152025-09-30
Janus Henderson Group Plc14.4%1,292,757SCHEDULE 13G, 2026-04-072026-03-31
Shaf QIC LLC10.01%10,534,639SCHEDULE 13G/A, 2025-07-312025-07-29
Deep Track Capital, LP9.99%902,561SCHEDULE 13G, 2026-02-062026-01-30
Trails Edge Capital Partners, LP9.9%933,477SCHEDULE 13G, 2026-02-102026-02-03
Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.7.8%696,378SCHEDULE 13G/A, 2026-08-132026-06-30
Wellington Management Group LLP7.8%696,378SCHEDULE 13G/A, 2026-08-132026-06-30
Sphera Funds Management Ltd.7.78%180,698SCHEDULE 13G/A, 2026-02-052025-12-31
Great Point Partners, LLC7.66%736,881SCHEDULE 13G/A, 2026-08-142026-06-30
Michael S. Gordon2%181,632SCHEDULE 13G/A, 2026-05-072026-03-31
Armistice Capital, LLC0.93%504,673SCHEDULE 13G/A, 2026-02-172025-12-31

Purpose of Transaction (Item 4)

ABG Management Ltd.

Item 4 is amended and supplemented by the following: CLOSING OF OFFERING On February 3, 2026, the previously disclosed Offering closed. REGISTRATION RIGHTS AGREEMENT On February 3, 2026, in connection with the closing of the Offering, the Issuer entered into a registration rights agreement (the "2026 Registration Rights Agreement") with the investors in the Offering, pursuant to which the Issuer is required to prepare and file a registration statement with the Securities and Exchange Commission covering the resale of the Common Shares issued to the investors pursuant to the Securities Purchase Agreement, together with the Common Shares underlying the Warrants. The foregoing description of the 2026 Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the form-of 2026 Registration Rights Agreement, which is attached as an exhibit to this Schedule 13D and incorporated herein by reference. REVERSE STOCK SPLIT The amount of Common Shares reported herein reflects a 1-for-25 reverse stock split that occurred on November 28, 2025.Item 4 of the SCHEDULE 13D/A filed 2026-02-05

Timeline

FiledHolderPercentFiling
2025-07-31Shaf QIC LLC10.01%SCHEDULE 13G/A
2025-08-04ABG Management Ltd.11.8%SCHEDULE 13G
2025-08-14Michael S. Gordon9%SCHEDULE 13G/A
2025-08-14Great Point Partners, LLC9.99%SCHEDULE 13G/A
2025-10-15Jeremy M. Sclar16.9%SCHEDULE 13G/A
2025-10-23Sphera Funds Management Ltd.5.51%SCHEDULE 13G/A
2025-10-29ABG Management Ltd.11.3%SCHEDULE 13D
2025-11-14Armistice Capital, LLC5.53%SCHEDULE 13G/A
2025-11-14Great Point Partners, LLC9.99%SCHEDULE 13G/A
2026-02-02ABG Management Ltd.11.3%SCHEDULE 13D/A
2026-02-05Sphera Funds Management Ltd.7.78%SCHEDULE 13G/A
2026-02-05ABG Management Ltd.17%SCHEDULE 13D/A
2026-02-06Deep Track Capital, LP9.99%SCHEDULE 13G
2026-02-10Trails Edge Capital Partners, LP9.9%SCHEDULE 13G
2026-02-17Great Point Partners, LLC9.99%SCHEDULE 13G/A
2026-02-17Armistice Capital, LLC0.93%SCHEDULE 13G/A
2026-03-18Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.9.99%SCHEDULE 13G
2026-04-07Janus Henderson Group Plc14.4%SCHEDULE 13G
2026-05-07Michael S. Gordon2%SCHEDULE 13G/A
2026-05-15Wellington Management Group LLP10%SCHEDULE 13G
2026-05-15Great Point Partners, LLC9.99%SCHEDULE 13G
2026-08-13Wellington Management Group LLP7.8%SCHEDULE 13G/A
2026-08-13Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.7.8%SCHEDULE 13G/A
2026-08-14Great Point Partners, LLC7.66%SCHEDULE 13G/A

Tools for this story

Each opens in a new tab, filled in for Promis Neurosciences Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/promis-neurosciences
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Promis Neurosciences Inc. 5%+ holders: 10 at 5% or more, largest ABG Management Ltd. 17%. MentionFox, 2026-09-27. https://mentionfox.com/stakes/promis-neurosciences